- Home
- DLXY vs ADXN Comparison
DLXY vs ADXN Comparison
Compare DLXY & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | ADXN |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 10.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | DLXY | ADXN |
|---|---|---|
| Price | $0.88 | $7.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.0K | 2.8K |
| Earning Date | 12-30-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1077.13 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $273,155,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $6.51 |
| 52 Week High | $7.16 | $12.05 |
Technical Indicators
Market Signals| Indicator | DLXY | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.76 |
| Support Level | N/A | $7.70 |
| Resistance Level | N/A | $8.37 |
| Average True Range (ATR) | 0.00 | 0.39 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 23.08 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.